| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/31/1994 | CA2110147A1 Method for treating systemic inflammatory response syndrome |
| 05/31/1994 | CA2110110A1 Use of certain methanebisphosphonic acid derivatives in fracture healing |
| 05/31/1994 | CA2109767A1 Strain of streptomyces for producing antiparasitic compounds and processes therewith |
| 05/31/1994 | CA2109764A1 C-11 modified pradimicin derivatives |
| 05/31/1994 | CA2109750A1 Method and pharmaceutical preparations for reducing the activity of cells |
| 05/31/1994 | CA1329937C 1-phenyl-3-naphthalenyloxypropanamines |
| 05/31/1994 | CA1329935C Imide derivatives, and their production and use |
| 05/31/1994 | CA1329932C Acyl deoxyribonucleoside derivatives and uses thereof |
| 05/28/1994 | CA2109993A1 Substituted derivatives of diaminophthalimide |
| 05/28/1994 | CA2109992A1 Phthalazinone derivatives |
| 05/28/1994 | CA2109975A1 Diaminobenzoic acid derivatives |
| 05/27/1994 | CA2109777A1 Schizophrenia |
| 05/26/1994 | WO1994011752A1 Functional radar warning receiver back-up generator |
| 05/26/1994 | WO1994011547A1 Process for the preparation of taxane derivatives, novel taxanes so obtained and antitumour and antileukaemia compositions containing same |
| 05/26/1994 | WO1994011535A1 Use of methioninase as an antitumor agent in anti-methionine chemotherapy |
| 05/26/1994 | WO1994011513A1 Heat shock proteins and the treatment of tumours |
| 05/26/1994 | WO1994011506A1 Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
| 05/26/1994 | WO1994011499A1 Flk-1 is a receptor for vascular endothelial growth factor |
| 05/26/1994 | WO1994011494A1 Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen |
| 05/26/1994 | WO1994011490A2 Products of the inhibition of advanced glycosylation |
| 05/26/1994 | WO1994011403A1 Artificial antibodies, method of producing the same and use thereof |
| 05/26/1994 | WO1994011387A2 A process for the production of finasteride |
| 05/26/1994 | WO1994011386A1 17-alpha and 17-beta substituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-alpha-reductase |
| 05/26/1994 | WO1994011385A1 17-alpha-acyl steroids which inhibit 5-alpha-reductase |
| 05/26/1994 | WO1994011381A1 Anti-proliferative and anti-inflammatory compounds: derivatives of pentose monosaccharides |
| 05/26/1994 | WO1994011380A1 Rapamycin carbonate esters as immunosuppressant agents |
| 05/26/1994 | WO1994011377A2 Water soluble camptothecin derivatives |
| 05/26/1994 | WO1994011370A1 Substituted amino alkyl compounds |
| 05/26/1994 | WO1994011368A1 Quinuclidine derivative as substance p antagonist |
| 05/26/1994 | WO1994011366A1 Oxidation of glycoside substituted taxanes to taxol or taxol precursors and new taxane compounds formed as intermediates |
| 05/26/1994 | WO1994011362A1 Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them |
| 05/26/1994 | WO1994011361A1 Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses |
| 05/26/1994 | WO1994011360A1 1,4-benzothiazepines useful as neurological agents |
| 05/26/1994 | WO1994011354A1 Tricyclic compounds with pharmaceutical activity |
| 05/26/1994 | WO1994011347A1 Phenyl-imidazolidinone derivatives, process for their preparation and their use as 5ht3 receptor antagonists |
| 05/26/1994 | WO1994011346A1 Aza spiro alkanes derivatives as therapeutic agents |
| 05/26/1994 | WO1994011343A1 Long chain fatty alcohols with neurotrophic and paramnesic activity, and method of preparation |
| 05/26/1994 | WO1994011342A1 Substituted arylalkynyl- and heteroarylalkynyl-n-hydroxyurea inhibitors of leukotriene biosynthesis |
| 05/26/1994 | WO1994011341A1 Substituted amidino compounds, their manufacture and methods of treatment |
| 05/26/1994 | WO1994011338A1 Use of n-arylmethylene, ethylenediaminetriacetates n-arylmethylene iminodiacentates or n, n'-diarylmethylene ethylenediaminacetates for use in combatting oxidative stress |
| 05/26/1994 | WO1994011337A1 Novel 3,3-diphenylpropylamines, their use and preparation |
| 05/26/1994 | WO1994011333A1 Succinic acid derivatives for use as skin conditioners |
| 05/26/1994 | WO1994011332A1 A novel arylpropionic derivative, a process for the preparation and the use thereof as an analgesic agent |
| 05/26/1994 | WO1994011045A1 Methods and pharmaceutical compositions for enhanced cardiopulmonary resuscitation |
| 05/26/1994 | WO1994011030A1 C-glycoside analogues of n-(4-hydroxyphenyl)retinamide-o-glucuronide |
| 05/26/1994 | WO1994011027A1 Peripheralization of hematopoietic stem cells |
| 05/26/1994 | WO1994011026A2 Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| 05/26/1994 | WO1994011012A1 Substituted dipeptide analogs promote release of growth hormone |
| 05/26/1994 | WO1994011011A1 Treatment of autoimmune diseases by inducing tolerance to cells, tissues and organs |
| 05/26/1994 | WO1994011006A1 Compositions for the regulation of cytokine activity |
| 05/26/1994 | WO1994011005A1 Viral attachment inhibitors |
| 05/26/1994 | WO1994011004A1 17 substituted acyl-3-carboxy 3,5-diene steroidals as 5-alpha-reductase inhibitors |
| 05/26/1994 | WO1994011002A1 8-epi prostaglandins |
| 05/26/1994 | WO1994011001A1 Hydroxyl-containing compounds |
| 05/26/1994 | WO1994011000A1 Xanthine derivatives for use as diuretics |
| 05/26/1994 | WO1994010999A1 Transdermal therapeutic system for administering physostigmin through the skin, and a method of producing the system |
| 05/26/1994 | WO1994010998A1 Method of manufacturing composition for solid medicine |
| 05/26/1994 | WO1994010997A1 Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them |
| 05/26/1994 | WO1994010996A1 Butenyl-substituted taxanes and composition |
| 05/26/1994 | WO1994010995A1 Antitumour compositions containing taxane derivatives |
| 05/26/1994 | WO1994010994A1 Ibuprofen salt effervescent compositions |
| 05/26/1994 | WO1994010993A1 Pharmaceutical formulations of ibuprofen |
| 05/26/1994 | WO1994010992A1 Prevention and amelioration of acetaminophen toxicity with beta-carotene |
| 05/26/1994 | WO1994010991A1 Ceramide derivatives |
| 05/26/1994 | WO1994010990A1 Inhibition of tnf production |
| 05/26/1994 | WO1994010989A1 Use of alpha-1c specific compounds to treat benign prostatic hyperplasia |
| 05/26/1994 | WO1994010988A1 An intravenous solution that diminishes body protein loss |
| 05/26/1994 | WO1994010987A1 Combined analgesic delivery methods for pain management |
| 05/26/1994 | WO1994010986A1 Transdermal delivery of ketorolac |
| 05/26/1994 | WO1994010985A1 Transdermal delivery of the eutomer of a chiral drug |
| 05/26/1994 | WO1994010984A1 TRANSDERMAL THERAPEUTIC SYSTEM FOR THE RELEASE OF 17-β-ESTRADIOL AND PROCESS FOR ITS PRODUCTION |
| 05/26/1994 | WO1994010982A1 Sustained-release microsphere containing antipsychotic and process for producing the same |
| 05/26/1994 | WO1994010981A1 Prolonged-action pharmaceutical preparation |
| 05/26/1994 | WO1994010977A1 Anti-microbial and interferon-inducing pharmaceutical compound |
| 05/26/1994 | WO1994008586A3 Azido derivatives of cyclopentane heptanoic or heptenoic acid |
| 05/26/1994 | WO1994008571A3 Plaster for the transdermal administration of volatile, pharmaceutically active, chemically alkaline ingredients, and processs for producing the same |
| 05/26/1994 | WO1994008002A3 Methods and compositions for controlling translation of hcv proteins |
| 05/26/1994 | WO1994004129A3 Cosmetic and dermatological sunscreen compositions containing thiols and/or thiol derivates |
| 05/26/1994 | WO1994004120A3 Methods of treating sexual dysfunction in animals with and h agonist |
| 05/26/1994 | WO1993025543A3 Enniatines and enniatine derivates used to control endoparasites |
| 05/26/1994 | DE4240672A1 Neues Verfahren zur Herstellung von beta-Carbolinen New process for the preparation of beta-carbolines |
| 05/26/1994 | DE4239150A1 O-acyl-4-phenyl-cyclohexanol derivs. - are inhibitors of 2,3-epoxy:squalene-lanosterol cyclase and useful as anti-hypercholesterolaemic for treating atherosclerosis |
| 05/26/1994 | DE4238223C1 Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung Transdermal therapeutic system for the administration of physostigmine to the skin, and process for its preparation |
| 05/26/1994 | CA2626445A1 Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| 05/26/1994 | CA2151617A1 Hydroxyl-containing compounds |
| 05/26/1994 | CA2149771A1 Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
| 05/26/1994 | CA2149669A1 Rapamycin carbonate esters as immunosuppressant agents |
| 05/26/1994 | CA2149515A1 Methods and pharmaceutical compositions for enhanced cardiopulmonary resuscitation |
| 05/26/1994 | CA2149431A1 Use of n-arylmethylene ethylenediamine-triacetates, n-arylmethylene iminodiacetates or n,n'-diarylmethylene ethylenediaminacetates against oxidizing stress |
| 05/26/1994 | CA2149427A1 17-alpha and 17-beta substituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-alpha-reductase |
| 05/26/1994 | CA2149309A1 Heat shock proteins and the treatment of tumours |
| 05/26/1994 | CA2149240A1 Process for preparing taxane derivatives; new taxanes thus produced and antitumoral and antileukemia compositions containing the same |
| 05/26/1994 | CA2149205A1 Anti-proliferative and anti-inflammatory compounds: derivatives of pentose monosaccharides |
| 05/26/1994 | CA2149116A1 Compositions for the regulation of cytokine activity |
| 05/26/1994 | CA2149043A1 Artificial antibodies, method of producing the same and use thereof |
| 05/26/1994 | CA2148930A1 Substituted amidino compounds, their manufacture and methods of treatment |
| 05/26/1994 | CA2148835A1 Treatment of autoimmune diseases by inducing tolerance to cells, tissues and organs |
| 05/26/1994 | CA2148819A1 Water soluble camptothecin derivatives |
| 05/26/1994 | CA2148687A1 Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen |
| 05/26/1994 | CA2148584A1 Therapeutic agents |